101328-85-2

101328-85-2 structure

Name: OR-1855
Chemical Name: (R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
CAS Number: 101328-85-2
Molecular Formula: C₁₁H₁₃N₃O
Molecular Weight: 203.240
Catalog: Research Areas Cardiovascular Disease
Create Date: 2019-01-04 21:03:44
Modify Date: 2025-08-20 11:31:52
OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure[1][2].

Name	(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Synonyms	3(2H)-Pyridazinone, 6-(4-aminophenyl)-4,5-dihydro-5-methyl- 6-(4-Amino-phenyl)-5-methyl-4,5-dih; ydro-2H-pyridazin-3-one (R)-6-(4-Aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone MFCD01692712 6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one 6-(4-Aminophenyl)-5-methyl-4,5-dihydro-3(2H)-pyridazinone Levosimendan Impurity 6

Description	OR-1855, an active metabolite of Levosimendan, has effect on human myometrial contractility. Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Others >> Others
References	[1]. Banfor PN, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H238-48. [2]. Mark P. Hehir, et al. 487: OR-1855, a levosimendan metabolite with an effect on human myometrial contractility.December 2009Volume 201, Issue 6, Supplement, Pages S182-S183.

Hazard Codes	Xi
HS Code	2933990090

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%